RDTCF (Rapid Dose Therapeutics) Gross Profit : $0.70 Mil (TTM As of Nov. 2024)

Rapid Dose Therapeutics Gross Profit Chart

Rapid Dose Therapeutics Annual Data
	Trend	Sep15	Sep16	Sep17	Sep18	Feb19	Feb20	Feb21	Feb22	Feb23	Feb24
Gross Profit		Get a 7-Day Free Trial					0.03	0.55	1.06	0.28	0.42

Rapid Dose Therapeutics Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Gross Profit	Get a 7-Day Free Trial															0.09	0.08	0.19	0.24	0.19

Competitive Comparison of Rapid Dose Therapeutics's Gross Profit

For the Biotechnology subindustry, Rapid Dose Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Gross Profit falls into.

Rapid Dose Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Rapid Dose Therapeutics's Gross Profit for the fiscal year that ended in Feb. 2024 is calculated as

Rapid Dose Therapeutics's Gross Profit for the quarter that ended in Nov. 2024 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.70 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Rapid Dose Therapeutics's Gross Margin % for the quarter that ended in Nov. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Rapid Dose Therapeutics  (OTCPK:RDTCF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rapid Dose Therapeutics had a gross margin of 53.76% for the quarter that ended in Nov. 2024 => Durable competitive advantage

Rapid Dose Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description